Cyclacel Pharmaceuticals (NASDAQ:CYCC) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.36, Zacks reports. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Trading Down 8.9 %

NASDAQ CYCC traded down $0.04 on Thursday, reaching $0.41. The stock had a trading volume of 507,616 shares, compared to its average volume of 711,483. Cyclacel Pharmaceuticals has a 1 year low of $0.37 and a 1 year high of $6.00. The business has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.44. The company has a market capitalization of $881,285.00, a price-to-earnings ratio of -0.05 and a beta of 0.56.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CYCC shares. StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a report on Thursday, November 7th. They set a “sell” rating on the stock. Roth Capital downgraded Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.